Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s

Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s

Submitted by admin on March 27, 2025 - 11:12am
Source: 
Clinical Trials Arena
News Tags: 
Acumen Pharmaceuticals
clinical trials
sabirnetug
Alzheimer's disease
Headline: 
Acumen concludes enrolment in Phase II trial of sabirnetug for Alzheimer’s
snippet: 

Acumen Pharmaceuticals has concluded enrolment for its multi-centre, double-blind Phase II ALTITUDE-AD trial of humanised monoclonal antibody sabirnetug (ACU193) for treating individuals with early Alzheimer’s disease.

Do Not Allow Advertisers to Use My Personal information